3 July 2025 Equity Research Report China's hog industry Equities Decreasing weight; stable sow inventories Hog weight reduction has had only a limited impact on prices in 2025. According to Sublime China Information (SCI), the average hog weight in China increased in 5M25; listed companies are following this trend. We believe the y-o-y increase in hog weight is motivated by the higher profit attained from larger hogs vs smaller hogs in 5M25. Although hog farmers are being encouraged to reduce the average we ...

The term weightless economy refers to the trade of products and services that are abstract or intangible, such as professional services. https://t.co/qC1WXamuQI ...

Geopolitical Landscape - BRICS nations have an opportunity to become a counterweight to Western-led institutions due to US President Donald Trump's policies and "America First" approach [1] - The lack of shared values and identity among BRICS nations may hinder their ability to become a meaningful global force [1]

Core Insights - TikTok is developing a SmartTV version aimed at major platforms like Samsung, Roku, and FireTV, indicating a strategic shift towards becoming a full video platform rather than just a social media app [1][2] - The company is targeting the growing Connected TV (CTV) advertising market, which is seeing a significant budget shift from mobile and traditional TV to CTV [8][9] - TikTok's entry into the CTV space is seen as a direct challenge to YouTube, which currently dominates the CTV advertising budget in the U.S. [3][4] Group 1: Market Dynamics - In 2024, an estimated 150 million people in the U.S. will use CTV to access YouTube, which has captured nearly 25% of the CTV ad budget [4] - Recent data shows that U.S. advertisers are now spending 43% of their CTV marketing budgets on YouTube, surpassing mobile ad spending for the first time [5] - The CTV advertising expenditure is expected to grow at a double-digit rate, with projections indicating a 16.8% increase by 2025, reaching $33.48 billion [15] Group 2: TikTok's Strategy - TikTok is likely to adopt a low-price strategy to penetrate the CTV market, leveraging the expanding CTV advertising budget [11][12] - The company may also explore revenue-sharing agreements with OEMs for pre-installation on smart TVs, similar to strategies used by Netflix and YouTube [21][29] - TikTok is expected to utilize a "light copyright" approach, focusing on short video content and partnerships rather than acquiring expensive IP rights [39][40] Group 3: Measurement and Data - To gain advertiser trust, TikTok plans to enhance its measurement capabilities, collaborating with Nielsen to provide unified reporting across different media [48][50] - The company aims to quantify the value of its advertising, making it easier for brands to compare TikTok's performance against competitors like YouTube [51][52] - TikTok's strategy involves a three-step approach: entering the market with lower CPMs, providing verifiable data, and gradually increasing prices as trust is established [52][53]

Group 1: Market Overview - The obesity drug market is projected to be worth $200 billion by 2031, presenting a significant growth opportunity for healthcare companies [1] - Eli Lilly and Novo Nordisk are currently the leaders in the GLP-1 weight loss drug space, generating billions in revenue from their approved products [11] Group 2: Clinical Trials and Drug Development - Amgen's MariTide, a monthly injection GLP-1 drug, has shown potential for weight loss of around 20% after one year in Phase 2 trials [6] - Recent Phase 2 trial results raised concerns due to a 27% discontinuation rate at the highest dosage because of gastrointestinal issues, although a slower dosage increase reduced this rate to less than 8% [6][7] Group 3: Competitive Landscape - The success of GLP-1 treatments hinges on patient tolerance; companies with better-tolerated treatments are likely to emerge as winners in the market [10] - If MariTide does not address side effect concerns, demand may be weak compared to established products from Eli Lilly and Novo Nordisk [11] Group 4: Investment Outlook - Amgen's stock was previously seen as an underrated growth opportunity, but recent data has led to a more cautious investment stance [12] - For investors seeking GLP-1 opportunities, Eli Lilly and Novo Nordisk are currently more favorable due to their proven products and potential for share price increases [13]

portfolio manager at JP Morgan Asset Management. Always happens when you when you least expect it, right. There was so much doom and gloom after those liberation day surprise high tariffs and look at the comeback we've made.Does it continue. Yeah, I got to we got to catch our breath after that quarter. I mean, you you showed that it was the best quarter for the for for the market in 5 years. Do you know it was the only quarter in the history of the S&P that we had a 10% draw down intraquarter only to finish ...

they're going to lose the listing either way. >> Yeah. But potentially good news for the US and the administration and other health care news.Some big changes are underway in the weight loss space. Starting today, CVS health will prioritize Novo Nordisk's Wegovy as the pharmacy's preferred GLP one drug and dropping Zepp from its list of covered drugs and a potential blow to Eli Lilly. Joining us now is Mizuho Healthcare strategist Jared Holt.Why does it have to be one or the other. Jared. >> Hey, Sara.Thank ...

China's homemade weight-loss drug, mazdutide, has been approved, and doctors hope it will help more patients get treatment https://t.co/zTXxsN61IH ...

Core Insights - CVS Health aims to build customer trust by enhancing access to affordable life-changing medications, specifically through the inclusion of Wegovy in its formularies and the support of its Weight Management program [1][8] Group 1: CVS Health's Strategy - CVS Caremark will add Wegovy, a GLP-1-based weight loss medication from Novo Nordisk, to its largest commercial formularies starting July 1 [1] - The company is removing Eli Lilly's Zepbound from its coverage to balance access and affordability amid rising demand for GLP-1 medications [2] - CVS plans to pair Wegovy with lifestyle clinical support as part of its Weight Management program, which has shown to reduce costs for clients by up to 26% [3] Group 2: Competitive Landscape - UnitedHealth Group's Optum Rx covers both Wegovy and Zepbound, and is working to simplify the pharmacy experience by eliminating up to 25% of reauthorizations [4] - Elevance Health's Carelon Rx has a digital weight management program that supports members using GLP-1 medications, contributing to a 15% growth in operating revenue [5] Group 3: Stock Performance - CVS Health shares have increased by 48.8% year-to-date, significantly outperforming the industry average of a 1.3% dip [6][8] - The stock is trading at a forward price-to-sales ratio of 0.21X, compared to the industry average of 0.40X, indicating an attractive valuation [9][8] Group 4: Earnings Estimates - The consensus estimate for CVS Health's 2025 earnings has been trending upward, while the estimates for 2026 remain mixed [10]

RT BBC Politics (@BBCPolitics)"We are beginning to roll out obesity drugs on the NHS"Health Secretary Wes Streeting says there is "potential" for most obese adults in the UK to end up using weight-loss drugs#BBCLauraK https://t.co/v2HwddQuYE https://t.co/YEbiPtZHfm ...